← Eichor
Study identifier: NCT05466825 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Global Cardiovascular Risk Consortium

Condition: All-cause Mortality · Cardiovascular Disease  ·  Sponsor: Universitätsklinikum Hamburg-Eppendorf

PhaseN/A
Planned participants3000000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersYes

About this study

The Global Cardiovascular Risk Consortium (GCVRC) brings together harmonized individual-level data from currently more than 2 million (anticipated: approximately 3 million) individuals across 133 cohorts, 40 countries, and 6 continents, with recruitment ongoing. The GCVRC examines the impact of classical cardiovascular risk factors-such as body-mass index, systolic blood pressure, non-high-density lipoprotein cholesterol, current smoking, and diabetes-on cardiovascular disease (CVD) and death from any cause worldwide.

This description comes directly from the study's public registry record.

Talk to the study team

Prof. Dr. med. Stefan Blankenberg  ·  +49 (0)40 741056800  ·  s.blankenberg@uke.de

Prof. Dr. med. Christina Magnussen  ·  +49 (0) 40 741058206  ·  c.magnussen@uke.de

Always discuss trial participation with your own doctor first.

Locations (1)

University Medical Center Hamburg-EppendorfHamburg, Free and Hanseatic City of Hamburg, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05466825